Dissertation > Excellent graduate degree dissertation topics show

Changes of Plasma Fibrinogen and D-dimer in Patients with Lung Cancer and the Influence of Interventional Treatment

Author: YingChunZhi
Tutor: LiCaiXia
School: Shandong University
Course: Medical Imaging and Nuclear Medicine
Keywords: fibrinogen D-dimer lung cancer intervention treatment
CLC: R734.2
Type: Master's thesis
Year: 2011
Downloads: 35
Quote: 0
Read: Download Dissertation

Abstract


Objective:To Investigate the difference of plasma fibrinogen between patients with lung cancer and normal control group, and to explore the clinical significance of changes in plasma fibrinogen and plasma D-dimer after interventional treatment.Materials and methods:1. Patient Selection:23 patients with lung cancer were all hospitalized patients pursuing interventional treatment. There were 16 males and 7 females, aged 45-75 years, mean age 63.5 years. All patients were diagnosed by pathology or cytology. Patients with heart, kidney, other lung diseases, diabetes and other underlying diseases were excluded. The normal control group was composed of 27 healthy volunteers, including 15 males,12 females, aged 30-74 years, mean age 50.4 years.2. Methods of treatment:All patients were treated with the bronchial artery infusion chemotherapy. The chemotherapy regimen was determined based mainly on histological type, All patients tolerated the treatment.3. Measurement of Plasma fibrinogen and D-dimer:All enrolled patients with lung cancer were measured plasma FIB and D-dimer before interventional therapy. Plasma FIB and D-dimer of the patients would be measured again in the interval between the second and third interventional procedure. Measurement method: Plasma FIB value was measured by coagulation theory. When there is a high concentration of thrombin, clotting time of Diluted test plasma levels is inversely proportional to its FIB. Blood D-dimer were tested by immunogold filtration assay principle.4. Statistical Methods:All statistical data are measurement data,and to be expressed as mean±standard deviation (x±s). Plasma FIB was compared pairwise matching, Chi-square test was used. Wilconxon test was used in the D-D test of significance due to variance missing of the data. All data were analyzed using spss16.0 software. Differences of P<0.05 were considered to be statistically significant.Result:1.Plasma FIB comparison between patients with lung cancer before Intervention treatment and the normal control group:Plasma FIB value of patients before intervention treatment(4.94±0.39)was significantly higher than that of the normal control group (2.86±0.09) (P<0.05).2. Plasma FIB comparison between patients with lung cancer before and after Intervention therapy:Plasma FIB before intervention therapy(4.94±0.39) was significantly higher than that after intervention therapy (2.93±0.11) (P<0.05).3. Plasma FIB comparison between patients with lung cancer after Intervention therapy and the normal control group:the difference of plasma FIB value of the group after intervention (2.93±0.11) and normal control group (2.86±0.09)was not significant.4. Plasma D-D comparison between patients with lung cancer before and after Intervention therapy:Plasma D-D Value of the group before intervention therapy (0.87±0.26) was significantly higher than that after intervention therapy (0.16±0.02) (P<0.05).Conclusion:Changes of plasma FIB and D-dimer in Lung cancer patients was significantly correlated with the severity of the disease and the effect of interventional therapy. The detection method is simple, fast, accurate, and sensitive, which can be used as a very meaningful indicator of interventional therapy.

Related Dissertations

  1. The Clinical Research for the Effect of Iodine-125 Seeds Implanted in Advanced Bronchial Lung Cancer,R734.2
  2. Effects of 5-Aza-2-deoxycytidine on DNA Methylation and Expression of p16 and MGMT Gene in Lung Cancer Cell Line SPC-A-1,R734.2
  3. Methylation of p16 Gene in Plasma and Tissues from Non-small Cell Lung Cancer Patients, Demethylation and the Biological Behavior of Lung Cancer Cell and Transcription of p16 Gene,R734.2
  4. The Clinical Value of Detection of Serum TPS, CEA, CYFRA21-1, NSE for Diagnosis in Patients with Lung Cancer,R734.2
  5. Study on the Expression and Correlation of Metallothionein and Matrix Metalloproteinase-2 in Non-small Cell Lung Cancer,R734.2
  6. The Effect of RNA Interference-mediated ERCC1 Gene on the Chemo-treatment Sensitivity of NSCLC in Vitro,R734.2
  7. Non-small Cell Lung Cancer Analysis of 133 Cases of CVATS Lobectomy,R734.2
  8. Clinical Observation of Pemetrexed for Treating Advanced Non-small Cell Lung Cancer,R734.2
  9. Combined Detection of Tumor Markers in the Diagnosis and Treatment of Lung Cancer to Determine the Clinical Significance,R734.2
  10. Exploreing the Mechanism of Xieshifeiaifang Ii on Treating Lung Cancer with Pleura Effusion,R734.2
  11. The Correlation Study among Fibrinogen, Apolipoprotein AⅠ Level and the Short-term Prognosis of Patients with Acute Coronary Syndrome after PCI,R541.4
  12. The Dynamic Changes of D-dimer Following Venous Thromboembolismin Rats,R543.6
  13. The Analysis of the M8000/3 Coder of the Lung Cancer Case in a Hospital Between 2006 to 2010,R734.2
  14. Expression of Chemokine Receptor CCR5 in Human Non-small-cell Lung Cancer,R734.2
  15. Influences of Cisplatin on Expressions of P-glycoprotein in the Resistance Cells of in Lung Cancer Xenografts in the Mice,R734.2
  16. Clinical Research on Detecing of the Combined Survivin mRNA with Cytokeratin 19(ck19) mRNA in Peripheral Blood of Non-small Cell Lung Cancer,R734.2
  17. The in Vitro Study of Serum-free Culture Combined DDP Enriching Human Lung Cancer Stem Cells,R734.2
  18. Effect of Rh-Endostatin on the Expression of ERCC1 in Human Lung Adenocarcinoma A549 Cells,R734.2
  19. The Investigation of Relationship between Therapeutic Effect and Prognosis and Changes of Peripheral Blood Vascular Endothelial Growth Factor and Metallothionein in Patients with Advanced Lung Cancer,R734.2
  20. The Molecular Biology of Rh-endostatin Plus Chemotherapy as Adjuvant Treatment for Non-small Lung Cancer,R734.2
  21. Effectiveness of Erlotinib as the Sennd-line Therapy in Patients with Advanced NSCLC,R734.2

CLC: > Medicine, health > Oncology > Respiratory system tumors > Lung tumors
© 2012 www.DissertationTopic.Net  Mobile